Lysyl-aspartyl-glutamyl-leucine

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 597464

CAS#: 113516-56-6

Description: Lysyl-aspartyl-glutamyl-leucine retains type II surface membrane proteins in the endoplasmic reticulum.

Chemical Structure

img
Lysyl-aspartyl-glutamyl-leucine
CAS# 113516-56-6
Instruction

Theoretical Analysis

MedKoo Cat#: 597464
Name: Lysyl-aspartyl-glutamyl-leucine
CAS#: 113516-56-6
Chemical Formula: C21H37N5O9
Exact Mass: 503.26
Molecular Weight: 503.550
Elemental Analysis: C, 50.09; H, 7.41; N, 13.91; O, 28.60

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Lysyl-aspartyl-glutamyl-leucine; Lys-asp-glu-leu; Kdel sequence;

IUPAC/Chemical Name: (S)-4-((S)-3-carboxy-2-((S)-2,6-diaminohexanamido)propanamido)-5-(((S)-1-carboxy-3-methylbutyl)amino)-5-oxopentanoic acid

InChi Key: JBFQOLHAGBKPTP-AJNGGQMLSA-N

InChi Code: InChI=1S/C21H37N5O9/c1-11(2)9-15(21(34)35)26-19(32)13(6-7-16(27)28)24-20(33)14(10-17(29)30)25-18(31)12(23)5-3-4-8-22/h11-15H,3-10,22-23H2,1-2H3,(H,24,33)(H,25,31)(H,26,32)(H,27,28)(H,29,30)(H,34,35)/t12-,13-,14-,15-/m0/s1

SMILES Code: CC(C)C[C@@H](C(O)=O)NC([C@H](CCC(O)=O)NC([C@H](CC(O)=O)NC([C@H](CCCCN)N)=O)=O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 503.55 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Zhang J, Xu R, Tao X, Dong Y, Lv X, Sun A, Wei D. TAT-IL-24-KDEL-induced apoptosis is inhibited by survivin but restored by the small molecular survivin inhibitor, YM155, in cancer cells. Oncotarget. 2016 Jun 14;7(24):37030-37042. doi: 10.18632/oncotarget.9458. PubMed PMID: 27203744; PubMed Central PMCID: PMC5095056.

2: Brychtová V, Vojtěšek B. [Endoplasmic Reticulum Chaperones at the Tumor Cell Surface and in the Extracellular Space]. Klin Onkol. Fall 2016;29 Suppl 4(Suppl 4):25-30. Review. Czech. PubMed PMID: 27846717.

3: Zhang J, Sun A, Xu R, Tao X, Dong Y, Lv X, Wei D. Cell-penetrating and endoplasmic reticulum-locating TAT-IL-24-KDEL fusion protein induces tumor apoptosis. J Cell Physiol. 2016 Jan;231(1):84-93. doi: 10.1002/jcp.25054. PubMed PMID: 26031207.

4: Takeda K, Qin SY, Matsumoto N, Yamamoto K. Association of malectin with ribophorin I is crucial for attenuation of misfolded glycoprotein secretion. Biochem Biophys Res Commun. 2014 Nov 21;454(3):436-40. doi: 10.1016/j.bbrc.2014.10.102. Epub 2014 Oct 27. PubMed PMID: 25451265.

5: Battelli R, Lombardi L, Picciarelli P, Lorenzi R, Frigerio L, Rogers HJ. Expression and localisation of a senescence-associated KDEL-cysteine protease from Lilium longiflorum tepals. Plant Sci. 2014 Jan;214:38-46. doi: 10.1016/j.plantsci.2013.09.011. Epub 2013 Sep 27. PubMed PMID: 24268162.

6: Hierl G, Höwing T, Isono E, Lottspeich F, Gietl C. Ex vivo processing for maturation of Arabidopsis KDEL-tailed cysteine endopeptidase 2 (AtCEP2) pro-enzyme and its storage in endoplasmic reticulum derived organelles. Plant Mol Biol. 2014 Apr;84(6):605-20. doi: 10.1007/s11103-013-0157-6. Epub 2013 Nov 28. PubMed PMID: 24287716; PubMed Central PMCID: PMC3950626.

7: Oh S, Tsai AK, Ohlfest JR, Panoskaltsis-Mortari A, Vallera DA. Evaluation of a bispecific biological drug designed to simultaneously target glioblastoma and its neovasculature in the brain. J Neurosurg. 2011 Jun;114(6):1662-71. doi: 10.3171/2010.11.JNS101214. Epub 2011 Feb 4. PubMed PMID: 21294620.

8: Acharya S, Hill RA. High efficacy gold-KDEL peptide-siRNA nanoconstruct-mediated transfection in C2C12 myoblasts and myotubes. Nanomedicine. 2014 Feb;10(2):329-37. doi: 10.1016/j.nano.2013.07.015. Epub 2013 Aug 6. PubMed PMID: 23928216.

9: Khan A, Fu H, Tan LA, Harper JE, Beutelspacher SC, Larkin DF, Lombardi G, McClure MO, George AJ. Dendritic cell modification as a route to inhibiting corneal graft rejection by the indirect pathway of allorecognition. Eur J Immunol. 2013 Mar;43(3):734-46. doi: 10.1002/eji.201242914. Epub 2013 Jan 18. PubMed PMID: 23212959; PubMed Central PMCID: PMC3615172.

10: Campbell-Valois FX, Trost M, Chemali M, Dill BD, Laplante A, Duclos S, Sadeghi S, Rondeau C, Morrow IC, Bell C, Gagnon E, Hatsuzawa K, Thibault P, Desjardins M. Quantitative proteomics reveals that only a subset of the endoplasmic reticulum contributes to the phagosome. Mol Cell Proteomics. 2012 Jul;11(7):M111.016378. doi: 10.1074/mcp.M111.016378. Epub 2012 Mar 15. PubMed PMID: 22427703; PubMed Central PMCID: PMC3394953.

11: Wang G, Norton AS, Pokharel D, Song Y, Hill RA. KDEL peptide gold nanoconstructs: promising nanoplatforms for drug delivery. Nanomedicine. 2013 Apr;9(3):366-74. doi: 10.1016/j.nano.2012.09.002. Epub 2012 Oct 2. PubMed PMID: 23041411.

12: Rocha AJ, Soares EL, Costa JH, Costa WL, Soares AA, Nogueira FC, Domont GB, Campos FA. Differential expression of cysteine peptidase genes in the inner integument and endosperm of developing seeds of Jatropha curcas L. (Euphorbiaceae). Plant Sci. 2013 Dec;213:30-7. doi: 10.1016/j.plantsci.2013.08.009. Epub 2013 Sep 5. PubMed PMID: 24157205.

13: Delie F, Petignat P, Cohen M. GRP78-targeted nanotherapy against castrate-resistant prostate cancer cells expressing membrane GRP78. Target Oncol. 2013 Dec;8(4):225-30. doi: 10.1007/s11523-012-0234-9. Epub 2012 Oct 23. PubMed PMID: 23090204.

14: Matsukawa S, Moriyama Y, Hayata T, Sasaki H, Ito Y, Asashima M, Kuroda H. KDEL tagging: a method for generating dominant-negative inhibitors of the secretion of TGF-beta superfamily proteins. Int J Dev Biol. 2012;56(5):351-6. doi: 10.1387/ijdb.123514sm. PubMed PMID: 22811269.

15: Lu Z, Lee KJ, Shao Y, Lee JH, So Y, Choo YK, Oh DB, Hwang KA, Oh SH, Han YS, Ko K. Expression of GA733-Fc fusion protein as a vaccine candidate for colorectal cancer in transgenic plants. J Biomed Biotechnol. 2012;2012:364240. doi: 10.1155/2012/364240. Epub 2012 May 23. PubMed PMID: 22675251; PubMed Central PMCID: PMC3366255.

16: Delie F, Ribaux P, Petignat P, Cohen M. Anti-KDEL-coated nanoparticles: a promising tumor targeting approach for ovarian cancer? Biochimie. 2012 Nov;94(11):2391-7. doi: 10.1016/j.biochi.2012.06.010. Epub 2012 Jun 17. PubMed PMID: 22713763.

17: Alanen HI, Raykhel IB, Luukas MJ, Salo KE, Ruddock LW. Beyond KDEL: the role of positions 5 and 6 in determining ER localization. J Mol Biol. 2011 Jun 10;409(3):291-7. doi: 10.1016/j.jmb.2011.03.070. Epub 2011 Apr 6. PubMed PMID: 21477593.

18: Cheung SC, Liu LZ, Lan LL, Liu QQ, Sun SS, Chan JC, Tong PC. Glucose lowering effect of transgenic human insulin-like growth factor-I from rice: in vitro and in vivo studies. BMC Biotechnol. 2011 Apr 12;11:37. doi: 10.1186/1472-6750-11-37. PubMed PMID: 21486461; PubMed Central PMCID: PMC3098155.

19: Lencer WI, Constable C, Moe S, Jobling MG, Webb HM, Ruston S, Madara JL, Hirst TR, Holmes RK. Targeting of cholera toxin and Escherichia coli heat labile toxin in polarized epithelia: role of COOH-terminal KDEL. J Cell Biol. 1995 Nov;131(4):951-62. PubMed PMID: 7490296; PubMed Central PMCID: PMC2200010.

20: Takahashi S, Izawa Y, Suzuki N. Astroglial pentose phosphate pathway rates in response to high-glucose environments. ASN Neuro. 2012 Mar 22;4(2). pii: e00078. doi: 10.1042/AN20120002. PubMed PMID: 22300409; PubMed Central PMCID: PMC3310304.